Ezetimibe plus simvastatin cardiovascular outcomes study program

References

• Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet366, 1267–1278 (2005).
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol.46, 1855–1862 (2005).
   PubMed Web of Science ®Google Scholar
• Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J. Am. Coll. Cardiol.49, 2003–2009 (2007).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350, 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Prospective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al.. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation106, 1943–1948 (2002).
   PubMed Web of Science ®Google Scholar
• Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int. J. Clin. Pract..58, 859–866 (2004).
   PubMed Web of Science ®Google Scholar
• Turley SD, Dietschy JM. The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Prev. Cardiol.6(1), 29–33, 64 (2003).
   PubMedGoogle Scholar
• Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol.90, 1092–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J.24, 729–741 (2003).
   PubMed Web of Science ®Google Scholar
• Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol.81, 582–587 (1998).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc.80, 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J.149, 464–473 (2005).
   PubMed Web of Science ®Google Scholar
• Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J.148, 447–455 (2004).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation.107, 2409–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Gagne C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation.105, 2469–7245 (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Guyton JR, Mazzone T et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin. Proc.81, 1579–1588 (2006).
   PubMed Web of Science ®Google Scholar
• Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am. J. Geriatr. Pharmacother.3, 218–228 (2005).
   PubMedGoogle Scholar
• Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am. J. Epidemiol.146, 483–494 (1997).
   PubMed Web of Science ®Google Scholar
• van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation109, 1089–94 (2004).
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol.87, 547–553 (2001).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am. Heart J.149(2), 234–239 (2005).
   PubMed Web of Science ®Google Scholar
• Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int.84(Suppl.), S207–S210 (2003).
   Google Scholar
• Foley RN, Parfrey PS, Sarnak M. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis.32(Suppl. 3), S112–S119 (1998).
   PubMed Web of Science ®Google Scholar
• Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med.351, 1285–1295 (2004).
   PubMed Web of Science ®Google Scholar
• Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis.15, 458–482 (1990).
   PubMed Web of Science ®Google Scholar
• Baigent C, for the UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the UK-Heart and Renal Protection (UK-HARP) Study. J. Am. Soc. Nephrol.13(Suppl.), 437A (2002).
   Google Scholar
• Keech A, Collins R, MacMahon S et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur. Heart J.15, 255–269 (1994).
   PubMed Web of Science ®Google Scholar
• Landray M, Baigent C, Leaper C et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am. J. Kidney Dis.47, 385–395 (2006).
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Allen C et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am. J. Cardiol.99, 970–973 (2007).
   PubMed Web of Science ®Google Scholar
• Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll. Cardiol.29, 630–634 (1997).
   PubMed Web of Science ®Google Scholar
• Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med.341, 142–147 (1999).
   PubMed Web of Science ®Google Scholar
• Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation104, 2205–2209 (2001).
   PubMed Web of Science ®Google Scholar
• Cowell SJ, Newby DE, Prescott RJ et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med.352, 2389–2397 (2005).
   PubMed Web of Science ®Google Scholar
• Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol.49, 554–561 (2007).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA292, 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, de Lemos JA, Cannon CP et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation113, 1406–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Kastelein JP et al. The ENHANCE Trial. Presented at: The 13th International Symposium on Atherosclerosis (ISA). Kyoto, Japan, 28–2 October (2003) (Abstract 1513).
   Google Scholar
• Rossebo A et al. Design of the simvastatin and Ezetimibe in aortic stenosis (SEAS) Study. Presented at: The 13th International Symposium on Atherosclerosis (ISA). Kyoto, Japan, 28–2 October (2003) (Abstract and Poster #3P-0870).
   Google Scholar